Serplulimab + Chemotherapy for Small Cell Lung Cancer
Trial Summary
What is the purpose of this trial?
This trial is testing two different treatment combinations for patients with extensive-stage small cell lung cancer who have not received any prior treatment. One group will receive a new drug called Serplulimab along with standard chemotherapy, while the other group will receive an existing drug called Atezolizumab with the same chemotherapy. Both immunotherapy drugs aim to help the immune system fight cancer, and the chemotherapy drugs work by killing cancer cells. Atezolizumab has been shown to improve survival in small-cell lung cancer when combined with chemotherapy, changing the standard first-line therapy.
Will I have to stop taking my current medications?
The trial information does not specify if you need to stop taking your current medications. However, if you are using denosumab for bone metastases, you must switch to bisphosphonate therapy before and during the trial.
What data supports the effectiveness of the drug combination Serplulimab plus chemotherapy for small cell lung cancer?
Is the combination of Serplulimab and chemotherapy generally safe for humans?
Serplulimab combined with chemotherapy has been shown to have a manageable safety profile in clinical trials for various cancers, including lung and esophageal cancers. While it can cause serious side effects in some patients, the overall safety is considered acceptable compared to chemotherapy alone.13678
How is the drug Serplulimab plus chemotherapy different for treating small cell lung cancer?
Serplulimab is an anti-PD-1 antibody that helps the immune system fight cancer by reducing immunosuppression, and when combined with chemotherapy, it has shown survival benefits for patients with extensive-stage small-cell lung cancer compared to chemotherapy alone. This combination is particularly novel as there is no standard treatment for transformed small cell lung cancer, making it a promising option for patients with this aggressive disease.123910
Eligibility Criteria
This trial is for US patients newly diagnosed with extensive-stage small cell lung cancer (ES-SCLC) who are fully mobile and have not received prior treatment. Eligible participants must not have other active cancers, except certain cured skin or in situ cancers, and should test negative for HIV, Hepatitis B/C. They cannot join if they've had a solid organ or bone marrow transplant, cervical/bladder/skin cancer, peripheral neuropathy, or brain metastasis.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive either Serplulimab or Atezolizumab plus chemotherapy (carboplatin-etoposide)
Follow-up
Participants are monitored for safety and effectiveness after treatment
Long-term follow-up
Participants are monitored for overall survival and progression-free survival
Treatment Details
Interventions
- Atezolizumab
- Carboplatin
- Etoposide
- HLX10
HLX10 is already approved in China, European Union for the following indications:
- Microsatellite Instability-High (MSI-H) solid tumors
- Squamous non-small cell lung cancer (sqNSCLC)
- Extensive-stage small cell lung cancer (ES-SCLC)
- Esophageal squamous cell carcinoma (ESCC)
- Extensive-stage small cell lung cancer (ES-SCLC)
Find a Clinic Near You
Who Is Running the Clinical Trial?
Shanghai Henlius Biotech
Lead Sponsor
Dr. Jason Zhu
Shanghai Henlius Biotech
Chief Executive Officer since 2023
MBA from Yale University
Dr. Jun Zhu
Shanghai Henlius Biotech
Chief Medical Officer
MD from an unspecified institution